448
Participants
Start Date
December 27, 2019
Primary Completion Date
September 27, 2021
Study Completion Date
September 27, 2021
MW031
"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
Placebo
"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
Peking Union Hospital, Beijing
Mabwell (Shanghai) Bioscience Co., Ltd.
INDUSTRY